R. Basser

发表

Strategies for prevention of anthracycline cardiotoxicity.

M. Green, R. Basser, Michael D. Green, 1993, Cancer treatment reviews.

Investigating the Effect of a Single Infusion of Reconstituted High-Density Lipoprotein in Patients with Symptomatic Carotid Plaques

D. Gaze, I. Loftus, M. Thompson, 2015, Annals of vascular surgery.

Phase I a nd P harmacokinetic S tudy o f P hotodynamic Therapy f or H igh-Grade G liomas U sing a N ovel Boronated P orphyrin

Michael R. Green, S. Stylli, A. Kaye, 2001 .

Phase I and Pharmacokinet ic Study of Photodynamic Therapy for High-Grade Gl iomas Using a Novel Boronated Porphyr

S. Stylli, A. Kaye, John S. Hill, 2000 .

Broad inter‐individual variations in circulating progenitor cell numbers induced by granulocyte colony‐stimulating factor therapy

C. Begley, A. Roberts, D. Metcalf, 1995, Stem cells.

A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer.

P. Mitchell, C. Begley, T. Kilpatrick, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine — Preliminary Report

C. Wichems, M. Greenberg, G. Hartel, 2009 .

Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.

J. Rasko, C. Begley, J. Zalcberg, 1997, Blood.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2007, British Journal of Cancer.

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

H. Hurwitz, D. Rischin, M. Rosenthal, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Reconstituted apoAI-phosphatidylcholine neutralizes atherothrombotic effects of C-reactive protein in humans

J. Kastelein, S. I. V. Leuven, E. Stroes, 2009 .

Clinical Studies of Thrombopoietin

R. Basser, 1999 .

New developments in high-dose chemotherapy for breast cancer.

R. Basser, 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

A Risk-Benefit Assessment of Anthracycline Antibiotics in Antineoplastic Therapy

M. Green, Michael D. Green, R. Abraham, 1996, Drug safety.

Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus

J. Kastelein, M. Nieuwdorp, T. Rabelink, 2008, Diabetologia.

Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers

M. Houghton, S. Coates, E. Maraskovsky, 2009, Human vaccines.

The Role of Platelet Growth Factors in Cancer Therapy

R. Basser, K. Clarke, 1996, Stem cells.

A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.

I. Davis, J. Cebon, M. Green, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimal dose of chemotherapy in adjuvant treatment of breast cancer

R. Basser, 2001 .

Failing to Live Up to the Fanfare? A Personal Perspective on Obstacles to the Clinical Development of Thrombopoietic Agents

C. Begley, R. Basser, 2001, International journal of hematology.

Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.

G. McArthur, D. Rischin, M. Rosenthal, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.

M. Rosenthal, J. Cebon, M. Green, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thrombopoietin

R. Basser, C. Underhill, 2001, BioDrugs.

Clinical biology and potential use of thrombopoietin.

R. Basser, 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Biologic and structural differences of thrombopoietic growth factors.

C. Begley, R. Basser, C.Glenn Begley, 2000, Seminars in hematology.

Thrombopoietin: an update on therapeutic potential.

R. Basser, C. Underhill, 1999, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG‐rHuMGDF

C. Begley, J. Rasko, C. O’Malley, 1997, British journal of haematology.

Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes.

M. Nieuwdorp, E. Stroes, M. Verhaar, 2007, Arteriosclerosis, thrombosis, and vascular biology.

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

I. Kerridge, Angel F. Lopez, H. Ramshaw, 2015, Leukemia & lymphoma.

Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans.

C. Begley, C. Begley, J. Cebon, 1997, Blood.

KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.

A. Kaye, M. Green, J. Hill, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRN8602 ( MX2-Hydrochlori de): A n A ctive N ew A gent f or t he Treatment o f R ecurrent H igh-Grade G lioma

A. Kaye, John S. Hill, Michael D. Green, 1999 .

Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.

C. Alt, A. Kaye, D. Morgan, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease

S. Stylli, A. Kaye, John S. Hill, 1998, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease

S. Stylli, A. Kaye, John S. Hill, 1997, Cancer Chemotherapy and Pharmacology.

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

C. Begley, J. Rasko, C. Begley, 1996, The Lancet.

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children

J. McVernon, P. Richmond, T. Nolan, 2009, Influenza and other respiratory viruses.

Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.

M. Green, G. Lieschke, W. Sheridan, 1991, Australian and New Zealand journal of medicine.

Small-cell lung cancer

P. Woll, T. le Chevalier, N. Thatcher, 2018 .

Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.

C. Begley, J. Collins, J. Szer, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent advances in carcinoids and gastrointestinal neuroendocrine tumors

Michael D. Green, R. Basser, 1991, Current opinion in oncology.

Combination of stem cell factor and granulocyte colony‐stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre‐colony‐forming unit (pre‐CFU) assay

C. Begley, P. Simmons, R. Basser, 2000, British journal of haematology.

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.

C. Begley, C. Begley, M. Edmonds, 2002, Blood.

Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.

C. Begley, J. Rasko, C. Begley, 1996, Blood.

Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.

C. Begley, J. Zalcberg, I. Davis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancement o f P latelet R ecovery A fter M yelosuppressive Chemotherapy b y R ecombinant H uman M egakaryocyte Growth a nd D evelopment F actor i n P atients With A dvanced C ancer

Michael R. Green, C. Begley, J. Zalcberg, 2000 .

Pharmacokinetic Analysis of Pegylated Megakaryocyte Growth and Development Factor in Humans

C. Begley, J. Cebon, L. Roskos, 2000, Growth factors.

Multicycle H igh-Dose C hemotherapy a nd Filgrastim-Mobilized P eripheral-Blood P rogenitor C ells in W omen W ith H igh-Risk S tage I I o r I II B reast C ancer: Five-Year F ollow-Up

C. Begley, J. Collins, J. Szer, 1999 .

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Colin Berry, Marc-André Lavoie, Jean-Claude Tardif, 2007, JAMA.

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

M. Zambon, P. Richmond, T. Nolan, 2008, Vaccine.

Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma.

J. Szer, A. Grigg, R. Basser, 1997, Australian and New Zealand journal of medicine.

Prolonged release and c‐kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor

C. Begley, L. To, P. Simmons, 1999, British journal of haematology.

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

J. Zalcberg, I. Davis, J. Cebon, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.

C. Begley, J. Collins, J. Szer, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

C. Wichems, M. Greenberg, G. Hartel, 2009, The New England journal of medicine.

Cytokines: Granulocyte colony-stimulating factor

J. Cebon, J. Layton, S. Nicholson, 1997 .

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

R Snyder, J F Forbes, J. Forbes, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

J. McVernon, H. Marshall, R. Booy, 2010, JAMA.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

D. Berry, S. Rodenhuis, J. Bergh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of thrombopoietin on clinical practice.

R. Basser, 2002, Current pharmaceutical design.

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

J. McVernon, M. Zambon, P. Richmond, 2008, Vaccine.

High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis.

C. Farquhar, A. Lethaby, J. Marjoribanks, 2007, Cancer treatment reviews.

Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin.

A H Kaye, R L Nation, S. Stylli, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem Cell Factor

G. Demetri, G. Tricot, C. Begley, 2000 .

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia.

I. Frazer, M. Quinn, S. Edwards, 2004, Vaccine.

Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.

L. To, M. Green, R. Abraham, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.

C. Begley, J. Collins, J. Szer, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dose-intensive chemotherapy in breast cancer--the need for appropriate measures of outcome.

R. Basser, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone?

C. Begley, A. Roberts, A. Grigg, 1995, Blood.

Conservative management of squamous cell carcinoma of the anal canal.

R. Basser, M. Guiney, J. Smith, 1994, The Australian and New Zealand journal of surgery.

Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancer

Michael D. Green, W. Sheridan, R. Fox, 2004, Cancer Chemotherapy and Pharmacology.

Early australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor

R. Basser, 1998, Stem cells.

Immunogenicity of a Monovalent 2009 Influenza A ( H 1 N 1 ) Vaccine in Infants and Children

J. McVernon, H. Marshall, R. Booy, 2009 .

ApoAI‐phosphatidylcholine infusion neutralizes the atherothrombotic effects of C‐reactive protein in humans

J. Kuivenhoven, J. Levels, R. Basser, 2009, Journal of thrombosis and haemostasis : JTH.

The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.

A. Goldhirsch, G. Viale, K. Price, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML

I. Lewis, P. Marlton, A. Roberts, 2008 .

Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies.

Basser, R. Basser, Abraham, 1997, The oncologist.

Isolated pleural effusion with hematopoietic cells of mixed lineage in a patient receiving granulocyte‐colony‐stimulating factor after high‐dose chemotherapy

I. Busmanis, R. Basser, A. Beaty, 1998, Diagnostic Cytopathology.

Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial.

W. Abhayaratna, J. McVernon, I. Barr, 2016, Vaccine.

High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer.

C. Farquhar, A. Lethaby, J. Marjoribanks, 2005, The Cochrane database of systematic reviews.

High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer.

C. Farquhar, A. Lethaby, J. Marjoribanks, 2005, The Cochrane database of systematic reviews.

Short communication Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancer

Michael R. Green, W. Sheridan, R. Fox, 1992 .

Response to a monovalent 2009 influenza A (H1N1) vaccine.

M. Greenberg, G. Hartel, R. Basser, 2009, The New England journal of medicine.

Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial.

W. Abhayaratna, J. McVernon, I. Barr, 2016, Vaccine.

Abnormal anal cytology in high-risk human papilloma virus infection in HIV-infected Australians

J. Hoy, G. Hartel, J. Anderson, 2007, Sexually Transmitted Infections.